The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases
1992

Effects of Sandostatin on Blood Flow in Liver Tumors

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): D.M. Hemingway, S.A. Jenkins, T.G. Cooke

Primary Institution: University Departments of Surgery, Glasgow Royal Infirmary and Royal Liverpool Hospital, UK

Hypothesis

Manipulation of hepatic blood flow may improve drug delivery to hepatic tumors.

Conclusion

Infusion of SMS 201-995 significantly decreased hepatic arterial flow while increasing the tumor:liver blood flow ratio.

Supporting Evidence

  • Infusion of SMS 201-995 resulted in a significant decrease in hepatic arterial flow.
  • The tumor:liver blood flow ratio was significantly increased after SMS infusion.
  • Blood flow to normal hepatic parenchyma was significantly reduced.

Takeaway

This study found that a drug called Sandostatin can change how blood flows in the liver, which might help deliver medicine better to liver tumors.

Methodology

Hepatic tumor was induced in rats, and blood flow was measured using a dual microsphere technique before and after SMS 201-995 infusion.

Limitations

The study was conducted in an experimental model, which may not fully represent human conditions.

Participant Demographics

Male Hooded Lister rats, weighing approximately 250g.

Statistical Information

P-Value

0.025

Statistical Significance

p=0.025

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication